Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reducing Risk of Dementia Through Deprescribing
Sponsor: Indiana University
Summary
A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.
Official title: Reducing Risk of Dementia Through Deprescribing (R2D2)
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
344
Start Date
2020-07-20
Completion Date
2026-07-30
Last Updated
2025-03-14
Healthy Volunteers
No
Conditions
Interventions
Deprescribing of target anticholinergics
The active intervention group (ACT) will receive a pharmacist-based deprescribing intervention focused only on targeted anticholinergic medications. The intervention pharmacist will serve as the central source of communication between participants, providers, and (as needed) dispensing pharmacy to coordinate the deprescribing process. The study pharmacists will navigate a shared-decision model between the physicians and participant in order to personalize the selection of appropriate alternatives and switch/titration schedules. Importantly, the pharmacist will supervise the titration and deprescribing plan and communicate with both participants and physicians throughout the study.
Usual Care
Those in the usual care group will not have access to the study intervention, but will receive a one-time information packet through the mail reviewing risks of polypharmacy, but no information specific to anticholinergic medications. They will receive clinical care as usually provided by their primary care or specialty care physicians.
Locations (2)
Indiana University Health
Indianapolis, Indiana, United States
Community Health Network Foundation, Inc.
Indianapolis, Indiana, United States